BioSpace News Archive

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of REMETRONIX. Terms of the transaction were not disclosed.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming conferences in January and February 2022.

Opiant Pharmaceuticals, Inc. announced the Compensation Committee of the Company’s Board of Directors has approved the grant of restricted stock units covering an aggregate of 31,500 shares of common stock to six hired employees, pursuant to the Company’s 2021 Inducement Equity Incentive Plan.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.

The global spine surgery products market is all set to gather noteworthy amounts in revenues in the forecast period of 2017 to 2025, states the recently published report by Transparency Market Research.

Increasing adoption of robotic assisted surgery is anticipated to fuel the demand in the global cervical cancer endoscopic devices market in coming years.

Fact.MR – A Market Research and Competitive Intelligence Provider: Rise in diabetic patients around the world has resulted in the global contact cast system market to grow steadily.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to a new study conducted by Fact.MR, the global byler disease market is expected to develop at a positive rate from 2021 to 2031.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that the first group of 15 patients have been enrolled and dosed in a Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans.

BENDIT Technologies, a company focused on the development of steerable microcatheters, announced today the successful first use in the USA of the BENDIT21 neuro catheter in a life-saving treatment.